Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer.
Publication/Presentation Date
4-23-2018
Abstract
Currently, treatment options for patients with advanced or recurrent endometrial cancer remain limited. The current standard of care treatment for advanced endometrial carcinoma is a platinum doublet chemotherapy. Second-line treatment options overall are very limited. There is no optimal treatment option for patients who show disease progression with first-line therapy. Therefore, novel and more efficacious therapies for patients with advanced or recurrent disease are needed. Immune checkpoint inhibitors have demonstrated a very impressive safety profile and anti-tumor activity in patients with programmed death-ligand 1 (PD-L1) positive endometrial cancer who were pre-treated with chemotherapy. We have done a detailed review of the literature to emphasize the role of immune checkpoint inhibitors in the treatment of metastatic or recurrent endometrial cancer.
Volume
10
Issue
4
First Page
2521
Last Page
2521
ISSN
2168-8184
Published In/Presented At
Arora, E., Masab, M., Mittar, P., Jindal, V., Gupta, S., & Dourado, C. (2018). Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. Cureus, 10(4), e2521. https://doi.org/10.7759/cureus.2521
Disciplines
Medicine and Health Sciences
PubMedID
29942724
Department(s)
Department of Obstetrics and Gynecology
Document Type
Article